Nimble Diagnostics has raised over €1 million in a round led by Grow Ventures and Namarel Ventures, with participation from Inveniam Group, members of CataloniaBio & HealthTech,who acted as a syndicate of various business angels.

Nimble is a MedTech spin-off from the Health Science Research Germans Trias i Pujol Institute (IGTP), also CataloniaBio & HealthTech members, the Polytechnic University of Catalonia (UPC), and the University of Barcelona (UB). In March 2022, Dr. Oriol Iborra (CEO) and Susana Amorós (CTO) founded the company together with a group of scientific researchers, with the aim of bringing its technology to the market.

Stentsare used to restore blood flow or other fluids. They are vital to prevent heart attacks or to treat their lasting symptoms. However, once implanted, over 30% become blocked or damaged, putting patient’s lives at risk. Current patient management is based on watching to see if the patient develops symptoms, by which time it is often too late to prevent significant damage or death, and in many cases involves a confirmatory invasive procedure and using X-ray radiation. Worldwide, it is estimated that more than 50 million people carry implanted stents, with an additional 4 million people implanted each year.

Nimble is currently developing a first in class medical device (NIMBLE System) for the continuous, non-invasive, low radiation monitoring of patients with implanted stents, shifting from reactive to proactive care. The technology is based on Microwave Spectrometry, a frequency scanning procedure that allows to measure and monitor stent status and malfunction, such in-stent restenosis, stent thrombosis, stent fracture, among others. The NIMBLE System is expected to enter the market in 2025, according to the company.

In this regard, the company has some important milestones to achieve before offering the NIMBLE System to primary care clinicians and cardiologists. This funding round will enable the completion of preclinical studies, team consolidation, regulatory studies, and the conduct of the first clinical trial at the Germans Trias i Pujol Hospital.

Photo: Nimble Diagostics